Transaction #14136 · Form 4 · 0001735276-25-000125
ALNYLAM PHARMACEUTICALS, INC. · Exercise / conversion · Common Stock
ALNYLAM PHARMACEUTICALS, INC. · Transacted November 26, 2025 · Filed December 1, 2025
What does this filing report?
An SEC Form 4 filing for ALNYLAM PHARMACEUTICALS, INC. records an exercise / conversion involving Common Stock on November 26, 2025. The reported quantity was 659. The filing date is December 1, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company CIK
- 0001178670
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 659
- Reported price
- 151.59
- Reference value
- 99,897.81
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 70,106
- Ownership description
- Not reported
- SEC acceptance time
- Dec 1, 2025, 4:10 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Greenstreet Yvonne ↗
Chief Executive Officer · Director
CIK 0001446125
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
- F2
- This stock option was fully vested and exercisable as of February 28, 2023.
- F3
- This stock option was fully vested and exercisable as of February 26, 2024.
- F4
- This stock option was fully vested and exercisable as of December 1, 2021.
- F5
- This stock option was fully vested and exercisable as of February 24, 2025.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.